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Abstract
The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is frequently activated in
human cancer and plays a crucial role in glioblastoma biology. We were interested in gaining further insight into the
potential of targeting PI3K isoforms as a novel anti-tumor approach in glioblastoma. Consistent expression of the PI3K
catalytic isoform PI3K p110a was detected in a panel of glioblastoma patient samples. In contrast, PI3K p110b expression
was only rarely detected in glioblastoma patient samples. The expression of a module comprising the epidermal growth
factor receptor (EGFR)/PI3K p110a/phosphorylated ribosomal S6 protein (p-S6) was correlated with shorter patient survival.
Inhibition of PI3K p110a activity impaired the anchorage-dependent growth of glioblastoma cells and induced tumor
regression in vivo. Inhibition of PI3K p110a or PI3K p110b also led to impaired anchorage-independent growth, a decreased
migratory capacity of glioblastoma cells, and reduced the activation of the Akt/mTOR pathway. These effects were selective,
because targeting of PI3K p110d did not result in a comparable impairment of glioblastoma tumorigenic properties.
Together, our data reveal that drugs targeting PI3K p110a can reduce growth in a subset of glioblastoma tumors
characterized by the expression of EGFR/PI3K p110a/p-S6.
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Introduction
Gliomas are the most common tumors of the central nervous
system, accounting for 80% of malignant brain tumors. Among
these, glioblastoma (GBM) represents the largest and most
malignant subgroup. GBMs are generally characterized by a
highly heterogeneous and highly infiltrative phenotype. Standard
treatment of care includes surgical resection, followed by radiation
and/or chemotherapy [1]. Despite this aggressive treatment,
almost all GBM eventually recur and the median survival of GBM
patients is only around one year [2,3]. Novel therapies are thus
urgently needed.
Genetic alterations in GBM predominantly include amplifica-
tions or mutations in the gene encoding the epidermal growth
factor receptor (EGFR). A rather characteristic mutation thereby
leads to the truncated version EGFRvIII, present in about 20% of
GBM [4], which possesses an in-frame deletion of exons 2 to 7 in
the extracellular domain and whose expression has been shown to
correlate with elevated downstream signaling activation [5,6].
Signaling via EGFR has also been demonstrated to contribute to
resistance of GBM to radiation and chemotherapy [7]. Further
growth factors have been described to play important roles in
GBM tumorigenesis. For instance, insulin-like growth factor I
(IGF-I) seems to be important in GBM chemoresistance, whereas
platelet-derived growth factor (PDGF) is thought to signal in an
autocrine fashion in GBM cells, thereby contributing to prolifer-
ation and survival of GBM tumor cells [8,9]. Due to the fact that
several different growth factors and their receptors play an
important role in GBM biology, the treatment of one receptor
alone might not lead to satisfying results. On the contrary,
targeting a signaling molecule downstream of these growth factors
might represent a successful treatment strategy.
The family of phosphoinositide 3-kinases (PI3Ks) lies down-
stream of several growth factor receptors. PI3Ks play an essential
role in signal transmission and they are crucial in controlling cell
proliferation, survival, and motility [10]. These enzymes phos-
phorylate membrane phosphoinositides on the inner side of the
cell membrane on the D3 position of the inositol ring. These 3-
phosphorylated membrane phosphoinositides then act as second
messengers which are important for the activation of the
downstream signaling pathway, including phosphorylation and
thereby activation of Akt [11]. Further accounting to the
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importance of PI3K signaling in cancer is the fact that the tumor
suppressor gene phosphatase and tensin homologue deleted on
chromosome 10 (PTEN) is frequently mutated in human cancers,
including GBM (approximately 20–30%) [10,12–15]. PTEN acts
as an antagonist of PI3K by dephosphorylating phosphatidylino-
sitol-3,4,5-trisphosphate and thus reducing downstream signaling
activity [16,17]. Additionally, PIK3CA, the gene encoding class IA
PI3K isoform p110a, has been shown to be mutated in GBM
tumor samples. PIK3CA mutations were found in 0–27% of GBM
tumor samples, depending on the study and the detection method
used [14,15,18–21]. Furthermore, and also depending on the
study and the method used, copy number increases of both
PIK3CA and PIK3CD (encoding PI3K p110d) have been reported
(ranging from approximately 0% to 60%) [14,19,21–23]. Taken
together, deregulation of the PI3K/Akt/mTOR pathway is
frequently detected in GBM (in around 88%) [12] and has been
found to contribute to a variety of cellular responses, thus
rendering this pathway and especially the PI3Ks interesting
candidates for targeted therapies.
In the present study, we have investigated the expression of class
IA PI3K isoforms in GBM tumor samples, cell lines, and ex vivo
cultures. We have further investigated the involvement of the
different isoforms in cell proliferation, survival, and migration.
Our results show that individual class IA PI3K isoforms have
selected cellular functions in GBM cells. The PI3K p110a had a
broad expression pattern in primary tumors and was associated
with the phosphorylation status of the ribosomal S6 protein, which
correlated with decreased patient survival. The PI3K isoform
p110a also appears to be essential for cell growth under
anchorage-independent conditions and in vivo. Targeting PI3K
p110b impaired anchorage-independent growth and cell migra-
tion in GBM cells, while targeting PI3K p110d was ineffective.
Thus the PI3K p110a and p110b isoforms appear to differentially
contribute to critical cell responses in GBM, which is important
when considering the future use of isoform-specific PI3K isoforms
in this devastating malignancy.
Materials and Methods
Glioma Tissue Microarray
The study cohort comprised of low and high grade glioma
samples from 103 patients operated at the Department of
Neurosurgery, University Hospital Zurich (Zurich, Switzerland).
Written informed consent was obtained from all the patients
before study entry. The procedures were conducted in accordance
with the Declaration of Helsinki and approved by the Ethics
Committee of the Canton Zurich. Paraffin blocks of these tumors
were reviewed by a neuropathologist and classified according to
the World Health Organization (WHO) of brain tumors [24].
Representative tumor areas were marked on hematoxylin/eosin-
stained slides and two cores (0.6 mm diameter) were punched
from the donor block and transferred into the tissue microarray
(TMA) recipient block, as recently described [25]. Additionally,
the TMA contained four normal brain samples (in duplicates) and
four cell lines (MCF-7, LN18, HT29, LN229). Normal brain tissue
specimens served as control and were derived from autopsy
material archived at the Institute of Neuropathology, University
Hospital Zurich (Zurich, Switzerland). According to the Ethics
Committee of the Canton Zurich, no ethical approval was
necessary, as the tissue samples were anonymized and used for
antibody validation and quality control of antibody immunosta-
ings. MCF-7 and HT-29 were purchased from the American Type
Culture Collection (Manassas, VA, USA) and the glioma cell lines
LN18 and LN229 were kindly provided by Dr. N. de Tribolet
(Lausanne, Switzerland) [26].
For immunohistochemistry (IHC) analysis freshly cut 3 mm
thick sections of the TMA block were mounted on SuperFrost
slides (Menzel Gla¨ser, Braunschweig, Germany). Primary anti-
bodies were incubated overnight at 4uC. The LSAB+System-HRP
kit (DAKO, Glostrup, Denmark) was used for primary antibodies
against PI3K p110a (1:200), p-Akt (S473) (1:50), p-S6 (S235/236)
(1:200) (all Cell Signaling, Danvers, MA, USA), and PI3K p110b
(1:100; Abcam, Cambridge, United Kingdom) according to the
manufacturer’s protocol. For antibodies against EGFR (1:50),
Akt1 (1:400), and S6 (1:100) (all Cell Signaling, Danvers, MA,
USA) N-Histofine Simple Stain MAX PO anti-rabbit (Nichirei
Biosciences, Tokyo, Japan) was used as a secondary antibody.
PTEN primary antibody (Cell Signaling, #9559, 1:100) was
applied in an automated stainer (Ventana Medical Systems,
Tucson, AZ, USA) according to a standard protocol (pretreatment
protocol ‘‘CC1m’’). Bound antibodies were detected by the
peroxidase method using diaminobenzidine as chromogen (760-
500, Ultraview DAB Detection Kit; Ventana Medical Systems,
Tuscon, AZ, USA). Finally, the slides were counterstained with
hematoxylin prior to dehydration and coverslipping.
IHC labeling of tumor cells in all samples was evaluated semi-
quantitatively by an experienced neuropathologist (C.H.) accord-
ing to the following criteria: no staining (0), slight staining intensity
of up to 30% of cells (1), slight to medium staining intensity of 30–
50% of cells (2), medium to strong staining intensity of at least 50%
of cells (3). Immunostaining scoring was performed in an entirely
blinded fashion.
Cases with clinical follow-up were evaluated with respect to
association of clinical factors and immunostaining scores to overall
survival (OS). OS was defined as date of diagnosis to death of any
cause or to the date of the last visit. Univariable analyses were
performed by the Kaplan-Meier method, and the log-rank test was
used for comparisons of survival in different groups [27]. Cox-
regression analysis was applied to analyze the correlation between
immunostaining and OS, adjusted for age, gender, and WHO
grade (for this analysis immunostaining scores were dichotomized
as immunopositive versus immunonegative). Further, the number
of positive immunostainings was summarized for both cascades
(EGFR, PI3K p110a/b, Akt1/p-Akt (S473)) and (PTEN, Akt1/p-
Akt (S473)), with negative values for positive PTEN staining since
PTEN antagonizes the activation of the signaling pathway. This
sum score was then compared between S6 and p-S6 (S235/236)
positive and negative patients, using permutation tests and
bootstrap means based on 109000 repetitions. All statistical
analyses were intended to be rather exploratory than confirmatory
and nominal p-values are reported, without adjustment for
multiple testing. p-values ,0.05, two-tailed are considered
statistically significant. Statistical analyses were performed using
SAS (Version 9.2 for Windows; SAS Institute Inc., Cary, NC,
USA) and PASW Statistics 18 for Windows (SPSS Inc., Chicago,
IL, USA).
Cell Lines and ex vivo Cultures
GBM cell lines were obtained from the American Type Culture
Collection and from Professor M. E. Hegi (CHUV, Lausanne,
Switzerland). PIK3CA mutated GBM cell lines SK-MG-17
(V344G) and SK-MG-26 (H1074Y) were kindly provided by
Professor G. Ritter (Ludwig Institute for Cancer Research, New
York Branch at MSKCC, New York, NY, USA) and have been
previously described [21]. GBM ex vivo cultures were established at
the Department of Neurosurgery of the University Hospital Zurich
(Zurich, Switzerland) as previously described [28]. All procedures
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conducted during the establishment of the ex vivo cultures were in
accordance with the Declaration of Helsinki and approved by the
ethics committee of the Canton Zurich. Informed written consent
was obtained from all patients. All GBM cell lines and ex vivo
cultures were cultured in Dulbecco’s modified Eagle’s medium
(Sigma-Aldrich, Buchs, Switzerland) supplemented with 10% (v/v)
heat-inactivated fetal calf serum, L-glutamine (Sigma-Aldrich,
Buchs, Switzerland), penicillin/streptomycin (GIBCO, Life Tech-
nologies Europe, Zug, Switzerland), and 10 mg/ml gentamycin
(Sigma-Aldrich, Buchs, Switzerland).
Western Blotting
Protein expression was analyzed by immunoblotting as
described previously [29] using antibodies against EGFR, PI3K
p110b, PI3K p110d, Akt1/2/3, caspase 3, ICAD, ERK (all Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA), PI3K p110a, p-
Akt (S473), p-Akt (T308), p-S6 (S235/236), p-S6 (S240/244), S6,
PARP, p-ERK (all Cell Signaling, Danvers, MA, USA), and b-
actin (Sigma-Aldrich, Buchs, Switzerland). Western blot analysis
was usually performed in duplicates or triplicates and represen-
tative blots are depicted.
Pharmacological Treatments and RNA Interference
Growth factors EGF, PDGF, and IGF-1 were obtained from
Calbiochem (Merck (Schweiz) AG, Zug, Switzerland). YM024
[30], PIK75 [31], TGX221 [32], and IC87114 [33] were
generously provided by Professor S. P. Jackson (The Australian
Centre for Blood Diseases, Monash University, Melbourne,
Australia). A66 was previously described [34]. BEZ235 [35] was
obtained from ChemieTek (Indianapolis, IN, USA). For growth
factor stimulation, cells were pretreated with 0, 1 mM YM024, or
1 mM TGX221 for 1 h. GBM cells were transfected with siRNA
pools (siGENOME SMART pool siRNA reagents; Dharmacon,
Lafayette, CO, USA) targeting PI3K p110a, PI3K p110b, PI3K
p110d, Akt1, Akt2, Akt3, S6K1, or Rac1 using DharmaFECT
siRNA transfection reagents (Dharmacon, Lafayette, CO, USA)
according to the manufacturer’s protocol. Dharmacon’s siGEN-
OME Non-Targeting siRNA Pool #2 (SCR) and TOX transfec-
tion control (TOX) were used as negative, non-targeting and
positive transfection control, respectively.
Cell Proliferation and Anchorage-independent Growth
Cell proliferation was assessed using the CellTiter 96 AQueous
One Solution Cell Proliferation Assay (Promega, Du¨bendorf,
Switzerland) according to the manufacturer’s protocol. Anchor-
age-independent growth was analyzed using soft agar assay. In
short, cells were grown in 0.35% agar supported on a 0.5% agar
layer in 6-well plates. Cells were overlaid with medium or the
appropriate treatment weekly. After 28 days, colonies were stained
with crystal violet and the number of colonies was counted. Cell
proliferation and anchorage-independent growth assays were
performed in quadruplets and triplicates, respectively. Individual
experiments were repeated up to three times, as indicated in the
corresponding figure legends.
Flow Cytometry
Apoptotic cells were assessed by flow cytometry as described
previously [36]. Adherent and floating cells were collected, stained
with FITC-labeled Annexin V (Biotium, Hayward, CA, USA) and
propidium iodide (PI), and analyzed on a BD LSR II flow
cytometer using BD FACSDiva software (Version 6.1.3; Becton
Dickinson AG, Allschwil, Switzerland) and FlowJo software
(Version 5.4+; Tree Star, Inc., Ashland, OR, USA). Flow
cytometry analysis measurements were performed in singlet with
three repetitions of individual measurements.
Cell Migration
For in vitro wound healing assays, a scratch was introduced into
a confluent layer of cells using a 200 ml pipette tip. The medium
was replaced with the appropriate treatment medium and plates
were further incubated. Photos were taken under a Nikon Eclipse
TS100 microscope (4 6 magnification) supplied with a Nikon
DXM1200 digital camera (Nikon ACT-1 2.70 software). Open
image area was quantified using TScratch software [37] and
wound closure was calculated by (open image area before
treatment - open image area after treatment). Random migration
experiments were performed as described [38]. Cell migration
experiments were performed in quadruplets and individual
experiments were repeated up to three times, as indicated in the
corresponding figure legends.
Chick Chorioallantoic Membrane Assay
Fertilized chicken eggs (gallus gallus) from a local hatchery were
incubated in a humidified incubator at 37uC. On embryonic day 3
(ED3), a window was opened in the shell and covered again with
tape to continue incubation. On ED7, a silicon ring was placed on
the chorioallantoic membrane (CAM), and around 3 million
T98G cells in 20 ml PBS were applied after gentle laceration of the
membrane. On ED10, photos were taken under a Leica M205 FA
microscope (106magnification) supplied with a Canon EOS 5D
Mark II camera (Canon EOS Utility software) and tumors were
treated with 20 ml of PI3K p110a-specific inhibitor PIK75 for four
consecutive days. On ED14, post-treatment photos were acquired
and the embryos were sacrificed. Tumor volume was estimated by
V~4=3pr
3, with r~1=2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(d1|d2)
p
[39].
Statistical Analysis of in vitro and in vivo Experiments
All statistical analyses of the in vitro and in vivo experiments were
performed using Instat+ for Windows (Version 3.036; Statistical
Services Centre, University of Reading, Reading, United King-
dom). Statistical significance between multiple groups was tested
with ANOVA and p,0.05 was considered significant. Statistical
significance between two groups was (subsequently) assessed by
two-sided, two-sample Student’s t-test. For experiments where
mean values were calculated over experiments with relative values
two-sided, one-sample Student’s t-tests were performed. The
individual statistical tests are indicated in the corresponding figure
legends.
Results
Glioma TMA and Correlation Studies
To investigate the expression of different components of the
PI3K/Akt signaling pathway in human glioma tissue, we
performed IHC analysis on a glioma TMA, containing samples
of 103 patients, ranging from WHO grade I (pilocytic astrocyto-
ma) to WHO grade IV (GBM) (Figure 1A and Table S1). Median
follow-up time across all patients was 1.6 years (589 days).
Complete disease information and IHC staining was available for
74 patients, while the other 29 patient were either lacking survival
data or complete IHC staining. Demographics and characteristics
of the 74 patients with complete information are summarized in
Table S1.
Univariable analysis (Table S2) revealed that patients with high
grade tumors (WHO grade.II) had a poorer 2-year OS when
compared to patients with low grade tumors (WHO grade # II;
Targeting Class IA PI3K Isoforms in Glioblastoma
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Figure 1. Expression analysis of proteins in the PI3K/Akt/mTOR signaling pathway in glioma and GBM samples. (A) IHC staining of
glioma tissue microarray demonstrating increased expression of all antigens shown in GBM (WHO grade IV) compared to pilocytic astrocytoma (WHO
grade I). Bars represent 100 mm. (B) Multivariable Cox-regression of IHC factors in 74 glioma patients by individually adding the immunostaining
status to the clinical factors age, gender, and WHO grade. Results for p-S6 (S235/236) and S6 are shown in the upper and lower panel, respectively.
HR: hazard ratio, LCL/UCL: lower/upper boundary of 95% confidence interval for HR. (C) Western blot analysis of protein levels of EGFR, PTEN, class IA
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32.2% versus 85.7%, p,0.001), which is consistent with previously
described findings and the current state of knowledge [1].
Figure 1A shows examples of IHC staining with PI3K p110a,
EGFR, S6, and p-S6 (S235/236) on two TMA positions,
representing stainings of a WHO grade I pilocytic astrocytoma
and a WHO grade IV glioblastoma and indicating increased
expression of all antigens shown in case of GBM. The majority of
glioma samples in the current study were immunopositive for
PI3K p110a (73% of all glioma and 83% of GBM), while
detection of PI3K p110b expression by IHC was infrequent (n = 1)
and detection of PI3K p110d was not possible due to the lack of
suitable antibodies.
Immunopositive tumors for EGFR (80%) and p-S6 (S235/236)
(42%) were frequently observed. The estimated 2-year OS for
patients with p-S6 (S235/236) immunopositive tumors (22.6%
versus 57.1%, p= 0.0043), with S6 immunopositive tumors (11.1%
versus 46.9%, p= 0.0216), or with EGFR immunopositive tumors
(OS 37.9% versus 60.0%, p= 0.0451) was less favorable when
compared to patients with immunonegative tumors. Detection of
p-Akt (S473) expression by IHC was infrequent (n = 1) in this
particular cohort, while immunonegative tumors for PTEN were
frequently observed (80%).
We next investigated the impact of immunostaining of
molecular factors on OS adjusted for important clinical factors
such as patients’ age, gender, and WHO grade. We added
individually the immunostaining status to the clinical factors and
applied multivariable Cox-regression analysis to estimate the effect
of immunostaining. We found that there was a trend for S6 and p-
S6 to be independently associated with worse OS when adjusted
for important clinical factors. (Figure 1B;the effects fos p-S6
(S235/236) and S6 are shown in the upper and lower part,
respectively).
To investigate which cascades (activation through EGFR and/
or through PTEN) contribute to the downstream activation/
phosphorylation of S6, we summarized the number of immuno-
positive staining of proteins in both cascades (EGFR, PI3K
p110a/b, Akt1/p-Akt (S473)) and (PTEN, Akt1/p-Akt (S473)),
using negative values for positive PTEN staining since PTEN
antagonizes the activation of the PI3K/Akt/mTOR pathway.
This analysis showed that patients with S6 positive tumors had
higher scores in the first cascade (mean difference = 0.77,
p = 0.0086) as well as in the second cascade (mean differ-
ence = 0.477, p = 0.0346). Contrary, patients with p-S6 (S235/
236) positive tumors had higher score values in the first cascade
(mean difference = 0.43, p = 0.0309) but not in the second cascade
(mean difference = 0.2672, p = 0.0805), indicating that down-
stream signaling was altered in our patient cohort by EGFR/
PI3K. The regulatory importance of PTEN was underlined when
the scores of the first pathway were compared in patients without
PTEN expression (PTEN IHC scoring = 0). In this subgroup of
patients those with S6 positive tumors had lower scores in the first
cascade (mean difference = 0.707, p = 0.0905); similarly p-S6
(S235/236) positive tumors had lower score values in the first
cascade (mean difference = 0.48, p = 0.0660). Since the number of
patients with PTEN expression (PTEN IHC scoring .0) was too
small (n = 15), the cascade analysis could not be performed for this
subgroup of patients.
Taken together, clinical factors (WHO-grade, gender, and age),
and molecular factors (immunopositive tumors for S6 and p-S6
(S235/236)) are associated with OS. Our data provide evidence
that the PI3K/mTOR/S6 signaling pathway can be activated
through expression of EGFR/PI3K p110a rather than through
reduced expression of PTEN in glioma.
Expression of PI3K Isoforms in GBM Cell Lines and ex vivo
Cultures
To gain an overview of the expression pattern of class IA PI3K
isoforms and the activation of the PI3K/Akt/mTOR signaling
pathway in GBM cell lines and ex vivo cultures, we performed
Western blot analysis on a set of seven GBM cell lines and seven ex
vivo (EV) cultures (Figure 1C and Tables S3 and S4). Protein
expression levels in GBM samples were compared to normal
human brain and cerebellum tissue as well as to immortalized type
II pneumocytes. While expression of the regulatory subunit PI3K
p85a was comparable to levels observed in control lysates,
differences in expression of the catalytic subunits PI3K p110a,
PI3K p110b, and PI3K p110d were found. PI3K p110a showed
the most striking variation with some samples showing overex-
pression (U251, T98G, EV5), while expression of this isoform was
nearly absent in certain cell lines (LN215, LN229, LN319) and ex
vivo cultures (EV1-4, EV6-7). The expression of the PI3K isoform
p110b was largely comparable to levels detected in control
samples. Interestingly, PI3K p110d was overexpressed in more
than half of all GBM cell lines analyzed (LN319, U87, U251,
U373), while the expression levels observed in ex vivo cultures were
comparable to the controls. Basal activation of Akt was detected
more frequently in cell lines (LN319, U87, U251, U373, T98G)
than in ex vivo cultures (EV5, EV7) when compared to control
samples. The most striking difference was found upon analysis of
S6 protein activation. Strong basal phosphorylation of this protein
was observed in all GBM cell lines and ex vivo cultures analyzed
when compared to control lysates.
Taken together, this expression analysis revealed that individual
catalytic class IA PI3K isoforms are overexpressed in GBM cell
lines and ex vivo cultures. Moreover, basal activation of the PI3K/
Akt/mTOR pathway was detected in the samples analyzed. While
phosphorylation of Akt was only observed in a subset of GBM cell
lines and ex vivo cultures, activation of S6 protein was observed in
all samples included in this study. These results confirm that the
PI3K/Akt/mTOR signaling pathway is aberrantly activated in
GBM.
Inhibition of PI3K Isoform p110a Impairs GBM Cell
Proliferation and Anchorage-Independent Growth
Based on the importance of PI3K/Akt signaling and the
deregulation of class IA PI3K isoforms, especially PI3K p110a, we
investigated the potential of pharmacological inhibition of theses
isoforms in GBM cell proliferation. GBM cell lines and ex vivo
cultures were treated with isoform-specific inhibitors YM024, A66,
PIK75 (all PI3K p110a), TGX221 (PI3K p110b), or IC87114
(PI3K p110d) for 72 h (Figure 2A and Figure S1A). Published IC50
values for PI3K p110 inhibition of these inhibitors are as follows:
300 nM for YM024 (PI3K p110a) [30], 32 nM for A66 (PI3K
p110a) [34], 6–7.8 nM for PIK75 (PI3K p110a) [31,34], 5–
12 nM for TGX221 (PI3K p110b) [30–32,34], and 41–500 nM
for IC87114 (PI3K p110d) [30,31,33,34]. While inhibition of
PI3K p110b or PI3K p110d did not show any significant effect on
cell proliferation of GBM cells, inhibition of PI3K p110a,
especially when using inhibitor PIK75 (the inhibitor with the
PI3K isoforms, and downstream signaling proteins Akt and S6 in human GBM cell lines and ex vivo cultures. Normal human brain and cerebellum
tissue as well as non-transformed type II human pneumocytes were used as controls.
doi:10.1371/journal.pone.0094132.g001
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lowest in vitro IC50 value), led to a dose-dependent decrease in cell
proliferation (Figure 2A and Figure S1A). To complement these
studies, GBM cells were transiently transfected with siRNA
targeting the three class IA PI3K isoforms (PIK3CA, PIK3CB, or
PIK3CD). The transfection with siRNAs led to a significant
downregulation at the mRNA and protein level (Figure S2). In
contrast to GBM cells with transiently downregulated PI3K p110b
or PI3K p110d, GBM cells transiently downregulated for PI3K
p110a showed impaired cell proliferation (Figure 2B and Figure
S1B). This confirms the results obtained with isoform-specific
pharmacological inhibitors and shows that PI3K p110a contrib-
utes to GBM cell proliferation.
Since PI3K p110a-specific inhibitors have been shown to
possess greater activity against tumor cell lines with a PIK3CA
mutated background [40], we analyzed cell proliferation in the two
PIK3CA mutated GBM cell lines SK-MG-17 (V344G) and SK-
MG-26 (H1047Y) in the presence of either one of the three PI3K
p110a-specific inhibitors YM024, PIK75, or A66 (Figure S3). The
two cell lines possess different PIK3CA mutations: SK-MG-26
(H1047Y) possesses a rare mutation at a hot spot in the C-terminal
portion of the kinase domain (H1047) which is known to lead to a
gain of function, while SK-MG-17 (V344G) possesses a rare and
not well characterized mutation in the C2 domain which is
thought to be part of the membrane-binding region of PI3K
p110a [21,41]. When compared to the PIK3CA wild type GBM
cell line T98G, SK-MG-26 (H1047Y) displayed a higher
sensitivity towards the PI3K p110a-specific inhibitors, which
was, however, not the case for SK-MG-17 (V344G).
Furthermore, anchorage-independent growth of GBM cells was
analyzed by means of a soft agar assay in the presence of class IA
PI3K isoform-specific inhibitors. Treatment with three different
PI3K p110a-specific inhibitors (YM024, A66, or PIK75) led to a
concentration-dependent decrease in the ability of GBM cells to
form colonies in soft agar (Figure 2C). Inhibition of PI3K p110b
(TGX221) also decreased the number of colonies formed
(Figure 2C), whereas the inhibition of PI3K p110d (IC87114;
Figure S4A) did not show significant effects on colony formation in
soft agar. These observations indicate that the PI3K isoforms
p110a and PI3K p110b play an important role in anchorage-
independent growth of GBM cells, and thus potentially in their
tumorigenic potential.
We further investigated cell proliferation and anchorage-
independent growth of GBM cells in the presence of the dual
PI3K/mTOR inhibitor BEZ235 (Figure 2D). A comparison of
these results with the PI3K p110a-specific inhibitors showed that
cell proliferation and colony formation in soft agar can be
significantly impaired by only inhibiting the PI3K isoform p110a,
instead of a combined inhibition of PI3K p110a and mTOR.
Thus, concomitant inhibition of PI3K p110a and mTOR might
not be necessary to impair growth in all GBMs.
Apoptosis
To analyze the cause of reduced cell proliferation of GBM cells
upon inhibitor treatment, we performed Western blot analysis of
apoptosis markers (caspase 3, ICAD, and cleaved PARP;
Figure 3A). According to these blots, the PI3K p110a-specific
inhibitor PIK75 induced PARP cleavage and decreased pro-
caspase 3 and ICAD-DIFF45 protein levels after 6 h of treatment,
indicating thereby that the reduction in cell proliferation is in part
due to the induction of apoptosis. The PI3K p110a-specific
inhibitor YM024 also induced PARP cleavage at a concentration
of 10 mM in one of the GBM cell lines tested. Flow cytometry
experiments confirmed the induction of apoptosis by the PI3K
p110a-specific inhibitor PIK75, as observed by an increase in
Annexin-V-positive/PI-negative cells after 8 h of treatment
(Figure 3B and C). Furthermore, the PI3K p110a-specific
inhibitor YM024 led to an increase in the number of cells in
early apoptosis, but to a lesser extent than PIK75. On the
contrary, treatment with the PI3K p110b-specific inhibitor
TGX221 did not lead to a significant increase in the number of
cells in early apoptosis (Figure 3C).
PI3K Isoforms p110a and p110b Play a Role in GBM Cell
Migration
In order to investigate the role of the different class IA PI3K
isoforms in GBM cell migration, we performed in vitro wound
healing assays by introducing a scratch into a confluent layer of
cells. Pharmacological inhibition of PI3K p110a significantly
impaired the ability of T98G and EV5 cells to migrate into the
open wound area (Figure 4A). Inhibition of PI3K p110b showed
even more prominent effects on GBM cell migration, inhibiting
wound closure already at lower concentrations (Figure 4A). In
contrast, pharmacological inhibition of PI3K p110d had no
significant effect on wound closure (Figure S4B). These results
indicate that PI3K isoforms p110a and p110b are involved in the
migratory potential of GBM cells.
To complement these studies, we transiently downregulated
individual class IA PI3K isoforms in T98G cells and investigated
random migration of these cells. Downregulation of the PI3K
isoform p110b (PIK3CB) negatively affected cell speed when
compared to control cells (SCR), while siRNA-targeting of PI3K
p110a or PI3K p110d (PIK3CA or PIK3CD) had no significant
effect (Figure 4B). Further, analysis of the distance covered by
T98G cells transfected with siRNA against PI3K p110b revealed a
highly restricted area of movement when compared to mock-
transfected cells (Figure 4C). Thus, PI3K p110b appears to
significantly contribute to the motility of GBM cells.
In order to assess the contribution of downstream signaling
components of the PI3K pathway to GBM cell migration, T98G
cells were transiently transfected with siRNAs targeting the three
Akt isoforms (Akt1-3), the ribosomal protein S6 kinase (S6K1), or
the small GTP-binding protein Rac1. Silencing Akt1 and S6K1
significantly reduced the migration speed of T98G cells, while
silencing Akt2 or Akt3 did not result in comparable effects
(Figure 4D). In contrast, silencing Rac1 significantly enhanced the
migration speed of T98G cells (Figure 4D). Thus, Akt1 and S6K1
most likely function downstream of class IA PI3K isoforms in the
control of cell migration in GBM cells.
PI3K p110a and PI3K p110b Inhibition Impairs Activation
of the Akt/mTOR Signaling Pathway
To investigate if pharmacological inhibition of PI3K p110a
successfully attenuates basal Akt/mTOR signaling pathway
activation, we performed Western blot analysis of GBM cells
treated with three different PI3K p110a-specific inhibitors
(YM024, A66, or PIK75). Indeed, all three inhibitors led to a
concentration-dependent decrease in the phosphorylation levels of
downstream Akt and S6 protein (Figure 5A). Additionally,
targeting of PI3K p110b with the isoform-specific inhibitor
TGX221 also led to a concentration-dependent decrease in the
phosphorylation levels of Akt and S6 protein (Figure 5B).
Numerous receptor tyrosine kinases (RTKs) are thought to
contribute to the malignant properties of gliomas through
autocrine signaling loops. Well documented growth factor systems
include the EGF system, the PDGF system and the IGF-I system
[9,42,43]. We were thus further interested in evaluating the
potential of PI3K p110-specific inhibition by YM024 (PI3K
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Figure 2. Inhibition of PI3K p110a impairs GBM cell proliferation and anchorage-independent growth. (A) Cell proliferation of GBM cells
in the presence of class IA PI3K isoform-specific inhibitors (72 h). (B) Cell proliferation of GBM cells transiently transfected with siRNA targeting class IA
PI3K isoforms p110a (PIK3CA), p110b (PIK3CB), or p110d (PIK3CD) 48 h post transfection. TOX and SCR siRNAs were used as positive and negative,
non-targeting controls, respectively. (C) Anchorage-independent growth (colony formation in soft agar) of GBM cells treated with PI3K p110a-specific
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p110a) or TGX221 (PI3K p110b) to affect growth factor-induced
pathway activation. Indeed, pre-treatment of T98G and EV7 cells
with YM024 impaired phosphorylation of Akt and S6 protein in
response to EGF, PDGF, or IGF-1 stimulation (Figure 5C).
Contrary to pharmacological inhibition of PI3K p110a, treat-
ments with the PI3K p110b-specific inhibitor TGX221 only
partially decreased phosphorylation of the ribosomal S6 protein
and not to the same extend as the PI3K p110a inhibitor YM024.
These results implicate that PI3K p110a plays a crucial role in
transmitting signals from activated RTKs and thus could be
involved in autocrine/paracrine signaling events in GBM.
Given the known existing cross-talks between the PI3K/Akt/
mTOR and the Ras/extracellular signal-regulated kinase (ERK)
signaling pathway, we performed Western blot analysis of the
GBM cells EV5, T98G, U87 and U251 after treatment with PI3K
isoform-specific inhibitors (6 h) and analyzed the phosphorylation
levels of ERK. These experiments showed no induction of ERK
phosphorylation upon treatment of GBM cells with PI3K isoform-
specific inhibitors and thereby indicate no feedback compensation
through the Ras/ERK signaling pathway (data not shown).
Pharmacological Inhibition of PI3K p110a Impairs T98G
Tumor Growth in vivo
To investigate the potential of PI3K p110a-specific inhibition
on tumor growth, we performed an in vivo CAM assay using T98G
GBM cells. Deposition of these cells on the CAM resulted in the
formation of solid tumors within three days (Figure 6A, before
treatment). Since the PI3K p110a-specific inhibitor PIK75
showed the most potent effects in the in vitro experiments, we
used this inhibitor in the in vivo setting. Indeed, treating the T98G
tumors formed on the CAM for four consecutive days with PIK75
led to decreased tumor sizes when compared to control treatment
(Figure 6A and B).
Discussion
The development of novel targeted therapies for GBM is of
crucial importance in view of the dismal prognosis of patients with
current treatment protocols. It has been recognized that the
PI3K/Akt/mTOR pathway is a very promising target for the
development of novel anti-cancer therapies in human cancer,
including GBM [44,45]. The most prominent mutations targeting
the pathway in GBM are in PTEN, PIK3CA, and EGFR [11–
13,18]. To date, the only agents that have been evaluated in GBM
clinical trials are allosteric mTOR inhibitors (analogs of rapamy-
cin, rapalogs), which have not shown significant activity, either as
single agents or in combination with standard chemotherapy
[11,44]. This may be explained by various factors, including the
multiple molecular mechanisms that exist which enable tumors to
develop resistance to allosteric mTOR inhibitors [46]. Therefore,
agents targeting Akt, PI3K, and mTOR may represent more
promising drugs to inhibit this pathway in GBM patients [46,47].
Indeed, there exist several reports on the pre-clinical activity of
Akt, PI3K, and mTOR inhibitors in GBM models, and several
clinical trials have been initiated with these novel agents
[11,44,45]. Concerning PI3K targeting, it has been generally
accepted that the dual targeting of PI3K p110a and mTOR is the
most potent strategy to inhibit the pathway in a variety of human
cancers, including GBM, by circumventing some of the feedback
loops which control tumor resistance to mTOR inhibitors [48]. In
addition, targeting class I PI3K isoforms has been recently shown
to have activity in GBM models, which was dependent on TP53
status [49]. Targeting the class IA PI3K isoform p110d was also
recently shown to impair the migration of GBM cells [50].
Another set of reports has demonstrated that PI3K p110b may be
the most relevant PI3K isoform to target in cancers which have
mutations in PTEN, such as GBM and prostate cancer [51,52]. So
far there is no consensus on the most relevant predictive
biomarkers for PI3K inhibitors in GBM, although there are
reports demonstrating that cancers with PIK3CA mutations are
most sensitive to these agents [53,54].
In this report, we show by IHC staining of a glioma TMA that
PI3K p110a is the class IA PI3K isoform which displays the most
consistent expression in GBM patient samples, in contrast to PI3K
p110b. Due to the lack of suitable antibodies, it was not possible to
assess the expression of PI3K p110d, which was previously
reported to be overexpressed at the mRNA level in primary GBM
[13,22]. In cell lines and ex vivo cultures, all three class IA PI3K
isoforms were expressed, indicating that GBM cell lines and ex vivo
cultures may up-regulate the expression of some PI3K isoforms,
such as PI3K p110b. When evaluating the contribution of the
expression of components of the EGFR/PI3K/Akt/mTOR
pathway to patient survival, it was found that phosphorylation of
ribosomal S6 protein was the best predictor of reduced patient
survival. In addition, co-expression of the EGFR/PI3K p110a/p-
S6 module was related to patient survival, indicating that the
activation of the pathway can influence GBM outcome. Interest-
ingly, this phenomenon was independent of PTEN and p-Akt
status, indicating that there exists a group of GBM tumors in
which the EGFR/PI3K/mTOR pathway is active by increased
expression of some components, such as EGFR and PI3K p110a.
On the other hand, GBM characterized by reduced or absent
PTEN expression may rely on another PI3K isoform, such as
PI3K p110b [51,52]. There are several reports which have
investigated the prognostic value of mutations in genes involved in
the PI3K signaling pathway as well as the activation status of Akt
and the ribosomal S6 protein in GBM. While there is no consensus
on the prognostic value of PTEN mutations or expression, the
phosphorylation status of the ribosomal S6 protein has been
previously inversely correlated to patient survival [7,55–57].
In view of the consistent expression of PI3K p110a in primary
GBM samples and its association with EGFR and mTOR
pathway activation, we next evaluated a panel of pharmacological
isoform-specific inhibitors in GBM cell lines and ex vivo cultures
expressing the EGFR/PI3K p110a/p-S6 module. In comparison
to the dual PI3K p110a/mTOR inhibitor BEZ235, PI3K p110a-
specific inhibitors displayed less potent activity when evaluated on
cells growing under adherent and optimal serum conditions. The
activity of the three PI3K p110a inhibitors in cells reflected their
potency for inhibition of PI3K p110a kinase activity in vitro. In
addition, some of the PIK3CA mutant GBM cell lines SK-MG-26
(H1047Y) responded better to the PI3K p110a-specific inhibitors
than GBM cell lines where PIK3CA is wild type. PIK3CA mutations
at position H1047 have been reported to predict sensitivity to
inhibitors of the PI3K pathway [53], which may explain the higher
sensitivity of the SK-MG-26 (H1047Y) cell line towards PI3K
inhibitors YM024, A66, PIK75, or PI3K p110b-specific inhibitor TGX221 (28 d). (D) Cell proliferation and anchorage-independent growth of GBM cells in
the presence of the dual PI3K/mTOR inhibitor BEZ235 (72 h and 28 d, respectively). Curves and bars represent the means of three individual
experiments 6 standard deviation; single experiment for soft agar assay with BEZ235; *: p#0.05, **: p#0.01, ***: p#0.001 compared to 0.0 mM
inhibitor or SCR non-targeting siRNA control as determined by two-sided, one-sample Student’s t-tests.
doi:10.1371/journal.pone.0094132.g002
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p110a-specific inhibitors. However, the activity of the PI3K p110a
inhibitors was not influenced by PTEN status. This was confirmed
by the observation that RNAi targeting PI3K p110a partially
reduced cell proliferation under adherent and optimal serum
conditions. In contrast, when assayed under anchorage-indepen-
dent conditions, the PI3K p110a and PI3K p110b inhibitors had
Figure 3. Inhibition of the PI3K isoform p110a with isoform-specific inhibitor PIK75 induces apoptosis. (A) Western blot analysis of
apoptosis markers of GBM cells following treatment with increasing concentrations of PI3K p110a-specific inhibitors YM024 or PIK75 (6 h). (B) Flow
cytometry analysis of T98G cells after treatment with PI3K p110a-specific inhibitor PIK75 (8 h) stained with Annexin-V and PI. (C) Quantification of
Annexin-V-positive/PI-negative T98G cells after treatment with PI3K p110a-specific inhibitors YM024, A66, PIK75, or PI3K p110b-specific inhibitor
TGX221 (8 h). Bars represent the means of three or two individual experiments6 standard deviation for PI3K p110a- or PI3K p110b-specific inhibitors,
respectively; ***: p#0.001 compared to 0.0 mM inhibitor as determined by two-sided, one-sample Student’s t-tests.
doi:10.1371/journal.pone.0094132.g003
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single agent activity in different GBM cell lines and ex vivo cultures.
In contrast, PI3K p110d inhibitors or siRNA did not show a
similar broad response in GBM, either under adherent or
anchorage-independent growth conditions. Furthermore, the
observation that PI3K signaling pathway inhibition impairs
anchorage-independent growth of GBM cells, by targeting PI3K
p110a or PI3K p110b, complements previously published data
investigating the role of Akt3 with respect to anchorage-
independent growth in GBM cells [58,59]. These investigations
show that GBM cell lines are dependent on Akt3 by means of
Figure 4. Class IA PI3K isoforms p110a and p110b play a role in GBM cell migration. (A) Analysis of the migratory potential of GBM cells by
means of wound healing assays in the presence of PI3K p110a or PI3K p110b-specific inhibitors (18 h). Bars represent the means of three individual
experiments 6 standard deviation; *: p#0.05, **: p#0.01, ***: p#0.001 compared to 0.0 mM inhibitor as determined by two-sided, one-
sample Student’s t-tests. (B) Migration speed of T98G cells in a random migration experiment following downregulation of class IA PI3K isoforms by
siRNA. *: p#0.05 compared to SCR non-targeting siRNA as determined by two-sided, one-sample Student’s t-test. (C) Distance of migration in a
random migration experiment of T98G cells transfected with non-targeting control (SCR) or PI3K p110b-targeting siRNA (PIK3CB). (D) Migration speed
of T98G cells in a random migration experiment following downregulation of PI3K/Akt signaling pathway molecules by siRNA. *: p#0.05, **: p#0.01
compared to SCR non-targeting siRNA as determined by two-sided, two-sample Student’s t-tests.
doi:10.1371/journal.pone.0094132.g004
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Figure 5. Pharmacological inhibition of PI3K p110a and PI3K p110b impairs downstream signaling. (A) Western blot analysis of basal
Akt/mTOR signaling activation by detection of phosphorylated downstream proteins Akt and S6 in GBM cells following treatment with increasing
concentrations of PI3K p110a-specific inhibitors YM024, PIK75, or A66 (6 h). (B) Western blot analysis of phosphorylated downstream proteins Akt and
S6 protein of GBM cells following treatment with increasing concentrations of the PI3K p110b-specific inhibitor TGX221 (6 h). (C) Growth factor-
induced PI3K/Akt signaling activation after pretreatment of T98G and EV7 cells with PI3K p110a-specific inhibitor YM024. (D) Growth factor-induced
PI3K/Akt signaling activation after pretreatment of T98G cells with PI3K p110b-specific inhibitor TGX221.
doi:10.1371/journal.pone.0094132.g005
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siRNA or shRNA downregulation of Akt3 and analysis of
anchorage-independent growth in soft agar.
When investigating the role of PI3K isoforms in GBM cell
migration, PI3K p110b appeared to play a major role. In contrast
to a recent report [50], PI3K p110d targeting by siRNA or
pharmacological inhibitors did not significantly impair GBM cell
migration. Contrary to previously published data stating that cell
migration of T98G GBM cells is dependent on Akt3 rather than
Akt1 or Akt2 [58], our assay showed that T98G GBM cell
migration depends on Akt1 rather than Akt2 or Akt3. The
discrepancy to this publication could be explained by the different
experimental setups: while we were using a random migration
assay on plastic with equivalent distribution of nutrients, Endersby
et al. used a nutrient-driven migration assay through matrigel.
Different nutrient environment as well as the presence of matrigel
might lead to the expression of different protein levels in the Akt
isoforms and might thus result in different cellular responses.
The induction of apoptosis was observed in GBM at high
concentrations of the PI3K p110a inhibitors, indicating that single
agent targeting of this isoform is not sufficient to induce cell death
under adherent conditions. This observation is supported by
previous studies, which have demonstrated that the induction of
cell cycle arrest is the most prominent mechanism of action of
these drugs, when used as single agents under adherent conditions
[35]. When evaluated in an in vivo model, the PI3K p110a
inhibitor PIK75 induced tumor regression of GBM, supporting the
view that single agent targeting of PI3K p110a may have anti-
tumor effects.
Together our data demonstrate that the PI3K p110a and PI3K
p110b isoforms appear to differentially contribute to critical cell
responses in GBM, which is important when considering the
future use of isoform-specific PI3K inhibitors. Drugs targeting
PI3K p110a may be considered for further evaluation in GBM, in
particular in tumors which express a functional EGFR/PI3K
p110a/p-S6 signaling module. These findings are important, since
at present it is unclear which drugs targeting the PI3K/Akt/
mTOR pathway have the most favorable profile in glioblastoma
patients and there are no robust predictive biomarkers for these
agents.
Supporting Information
Figure S1 Cell proliferation of GBM cells after targeting
of class IA PI3K isoforms. (A) Cell proliferation of GBM cells
in the presence of class IA PI3K isoform-specific inhibitors (72 h).
(B) Cell proliferation of GBM cells transiently transfected with
siRNA targeting class IA PI3K isoforms p110a (PIK3CA), p110b
(PIK3CB), or p110d (PIK3CD). TOX and SCR siRNAs were
used as positive and negative, non-targeting controls, respectively.
Curves and bars represent the means of three individual
experiments 6 standard deviation; *: p#0.05, **: p#0.01
compared to SCR non-targeting control siRNA as determined
by two-sided, one-sample Student’s t-tests.
(TIF)
Figure S2 Transient transfection of GBM cells with
siRNA targeting specific class IA PI3K isoforms. Transient
transfection of T98G (A) and EV5 (B) cells with siRNA targeting
class IA PI3K isoforms p110a (PIK3CA), p110b (PIK3CB), or
p110d (PIK3CD) leads to target downregulation at the mRNA
level (upper panels) and protein level (lower panels) 48 h post
transfection. Bars represent the means of three individual
experiments 6 standard deviation; **: p#0.01, ***: p#0.001
compared to SCR non-targeting control siRNA as determined by
two-sided, one-sample Student’s t-tests
(TIF)
Figure S3 PI3K p110a-specific inhibitor treatment of
PIK3CA wild type and PIK3CA mutated GBM cell lines.
PIK3CA wild type GBM cell line T98G and PIK3CA mutated
GBM cell lines SK-MG-17 (V344G) and SK-MG-26 (H1047Y)
were treated with PI3K p110a-specific inhibitors YM024, PIK75,
or A66 (72 h). Curves represent the means of three independent
Figure 6. PI3K p110a-specific inhibition of T98G tumors formed on the chick chorioallantoic membrane impairs tumor growth. (A)
Representative pictures of T98G tumors formed on the CAM three days post cell application (106magnification). Tumors were treated with PIK75 as
indicated for four consecutive days. (B) Quantification of changes in tumor volume before and after PIK75 or control treatment. Lines indicate the
mean of each group. *: p = 0.02 compared to control treatment as determined by two-sided, two-sample Student’s t-test.
doi:10.1371/journal.pone.0094132.g006
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experiments 6 standard deviation. *: p#0.05, **: p#0.01
compared to T98G cells as determined by two-sided, one-sample
Student’s t-tests.
(TIF)
Figure S4 Soft agar colony formation assay and wound
healing assay of GBM cells. (A) Anchorage-independent
growth (colony formation in soft agar of GBM cells in the presence
of PI3K p110d-specific inhibitor IC87114 (28 d). (B) Analysis of
the migratory potential of GBM cells by means of wound healing
assays in the presence of PI3K p110d-specific inhibitor IC87114
(18 h). Bars represent the means of three individual experiments6
standard deviation.
(TIF)
Table S1 Demographics and disease characteristics of
74 patients with complete disease and IHC information.
(PDF)
Table S2 Univariable analyses of 74 patients with
complete disease and IHC information.
(DOC)
Table S3 Genetic background information about the
GBM cell lines used in this study.
(PDF)
Table S4 Additional information about the GBM ex vivo
cultures used in this study.
(PDF)
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